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ABSTRACT
Brain metastases develop in one-third of patients with non-small-cell lung 
cancer and are associated with a dismal prognosis, irrespective of surgery or chemo-
radiotherapy. Pathological markers for predicting outcomes after surgical resection 
and radiotherapy responsiveness are still lacking. Caveolin 1 has been associated 
with chemo- and radioresistance in various tumors, including non-small-cell lung 
cancer. Here, caveolin 1 expression was assessed in a series of 69 brain metastases 
from non-small-cell lung cancer and matched primary tumors to determine its role 
in predicting survival and radiotherapy responsiveness. Only caveolin 1 expression 
in brain metastasis was associated with poor prognosis and an increased risk of 
death (log rank test, p = 0.015). Moreover, in the younger patients (median age of 
<54 years), caveolin 1 expression neutralized the favorable effect of young age on 
survival compared with the older patients. Among the radiotherapy-treated patients, 
an increased risk of death was detected in the group with caveolin 1-positive brain 
metastasis (14 out of 22 patients, HR=6.839, 95% CI 1.849 to 25.301, Wald test p = 
0.004). Overall, caveolin 1 expression in brain metastasis from non-small-cell lung 
cancer is independently predictive of worse outcome and radioresistance and could 
become an additional tool for personalized therapy in the critical subset of brain-
metastatic non-small-cell lung cancer patients.
INTRODUCTION
Brain metastasis from non-small-cell lung cancer 
(NSCLC), the leading cause of cancer-related death 
worldwide, develops in 20-40% of patients [1, 2] at a 
relatively earlier stage compared with other primary 
cancers. It is associated with a dismal prognosis, with 
a median survival of one month in untreated patients. 
Other than supportive care with corticosteroids, surgery, 
whole-brain radiation therapy (WBRT), stereotactic 
radiosurgery and chemotherapy, either alone or in various 
combinations, are valuable options for these patients 
[3]. Although WBRT is still the most effective treatment 
following surgery [3], the overall survival is about five 
months after WBRT, and only 5% of patients survive one 
year [4, 5]. Prognostic factors affecting survival include 
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age, performance status, the number, locations, and sizes 
of brain metastases, the presence or absence of symptoms 
and/or mass effect, suitability for surgical resection, and 
availability (or not) of options for controlling extracranial 
disease [6]. However, pathological tools for selecting 
patients who may benefit from surgical resection of brain 
metastasis, for predicting outcomes after surgical resection 
and for predicting radiotherapy responsiveness are lacking.
Among various prognostic and predictive 
markers, caveolin 1 (Cav1) has been associated with 
chemoresistance in various solid tumors, including 
NSCLC [7, 8, 9], and with radioresistance in 
pancreatic [10, 11] and colon cancers [12]. Cav1 is 
an essential structural constituent of caveolae, acting 
as a multifunctional scaffolding protein with multiple 
binding partners. Its ability to interact with numerous 
proteins makes it a central cellular signaling molecule. 
Cav1 organizes signaling complexes at the inner plasma 
membrane to activate a variety of cellular events and has 
been implicated in neurodegenerative diseases, diabetes 
mellitus, senescence and oncogenesis [13]. In cancer, 
Cav1 is involved in cellular transformation, tumor growth, 
cell death and survival, multidrug resistance, angiogenesis, 
cell migration and metastasis [14]. A biphasic role of Cav1 
in signal transduction and cancer has been thoroughly 
documented. It acts as a tumor-suppressing protein during 
the early stages of cancer progression, but once it becomes 
upregulated during more advanced stages of disease, 
it gains an oncogenic function, which contributes to an 
aggressive and metastatic phenotype [14]. In agreement 
with this oncogenic potential, in vitro Cav1 knockdown 
of NSCLC cells has been shown to result in inhibition of 
cellular proliferation [15], whereas Cav1-overexpressing 
NSCLC cells, as well as anoikis-resistant cells, exhibit 
enhanced metastatic activity [16]. Meta-analysis of 
NSCLC patients [17] has revealed that although the 
Cav1 level is significantly lower in cancerous tissues 
than in non-neoplastic lung tissues, Cav1-expressing 
NSCLC patients have a higher risk of death and reduced 
progression-free survival, consistent with a role of Cav1 
in tumor progression. We have previously described the 
differential expression of Cav1 according to NSCLC 
histotype and its increased expression in brain metastasis 
[18].
To the best of our knowledge, neither a hypothetical 
prognostic role of Cav1 expression in brain metastasis 
from NSCLC nor its relationship with response to 
radiotherapy has been assessed. Therefore, we evaluated 
the role of Cav1 in predicting survival and radiotherapy 
responsiveness in 69 patients with NSCLC with brain 
metastasis. We found that a) Cav1 expression in brain 
metastasis was related to poor prognosis; b) in younger 
patients, Cav1 expression in brain metastasis resulted in an 
increased risk of and neutralization of the favorable impact 
of young age on survival; and c) Cav1 positivity in brain 
metastasis was predictive of radioresistance.
RESULTS
Clinico-pathological data and Cav1 protein 
expression
The main clinical and pathological features of the 
whole series of 69 cases are summarized in Table 1. A 
total of 38 cases (55%) were adenocarcinomas. Cav1 
expression in primary lung carcinoma and matched brain 
metastasis exhibited a significant association (chi-square 
test p < 0.001). Overall, 16 (23%) primary tumors and 
28 brain metastases (41%) expressed Cav1, with mild to 
strong membrane or cytoplasmic staining of neoplastic 
cells (Figure 1). Fourteen negative primary tumors 
shifted to Cav1 positivity during metastasis, whereas 
two positive lung carcinomas lost Cav1 expression in the 
brain metastatic tissue (Table 2). Cav1 brain metastasis 
expression and histotype were significantly associated 
(chi-square test p = 0.043) because all of the brain 
Table 1: Clinical and pathological features of 69 patients with NSCLC metastatic to the brain analyzed for Cav1 
expression
Parameter
M/F ratio 3.31
Age, mean (years) [range] 64 [35-80]
Number of brain metastases single: 49multiple: 20
Histotype
adenocarcinoma: 38
squamous cell carcinoma: 14
neuroendocrine carcinoma: 7
large cell carcinoma: 10
Type of radiotherapy adjuvant : 22cytoreductive: 9
Disease status (lost to FU: 1) NED/DOC: 14DOD: 57
Median overall survival  (months) 14 [1-84]
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neuroendocrine tumors (7 cases) were negative for Cav1 
expression. Analysis of the differential expression of 
Cav1 by histotype revealed that all of the positive primary 
adenocarcinomas (7 cases) maintained Cav1 expression at 
the brain metastatic site and that 7 out of 31 acquired Cav1 
expression during metastasis (chi-square test p < 0.001) 
Table 2: Distribution of Cav1 positivity in primary tumors and brain metastases
Primary tumor Metastasis Sum pCav1 negative Cav1 positive
Cav1 negative 39 14 53
p < 0.001Cav1 positive 2 14 16
Sum 41 28 69
Figure 1: Representative examples of two brain metastasis from lung adenocarcinoma (A, C hematoxylin & Eosin, 
original magnification 400X) with mild to strong membrane-cytoplasmic immunoreactivity and negative staining for 
Cav1 (respectively B, D original magnification 400X) and high CAV1 gene polysomy by FISH analysis (E).
Oncotarget29629www.impactjournals.com/oncotarget
(Table 3). No association of Cav1 expression was found 
for squamous cell or large cell carcinoma histotype (Table 
4). 
Cav1 mutation and FISH analyses
Fifty-four cases were suitable for mutational 
Figure 2: Survival curves showing that grouping by histotype was not a significant predictor for survival (Log rank 
test, p=0.233, 2A). Conversely, adenocarcinoma was associated with prolonged survival when other histotypes were considered together 
(Log rank test, p=0.056, 2B).
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analysis. The Cav1 P132L mutation was found in two 
lung adenocarcinomas, only one of which retained the 
mutation at the metastatic site. Interestingly, this case had 
a negative immunohistochemistry result, whereas the other 
case showed positive results at the primary and secondary 
sites. FISH analysis was performed on 16 matched cases, 
Table 3: Differential expression of Cav1 by histotype and site
Primary lung cancer p Brain metastasis pCav1 negative Cav1 positive Cav1 negative Cav1 positive
Adenocarcinoma
Squamous cell
Neuroendocrine
Large cell
31
9
7
6
7
5
0
4
0.143
24
6
7
4
14
8
0
6
0.043
Table 4: Correlation between Cav1 expression at primary and metastatic sites in adenocarcinoma histotype
Primary tumor
adenocarcinoma
Metastasis p
Cav1 negative Cav1 positive
Adenocarcinoma Cav1 negative 24 7 p < 0.001Cav1 positive 0 7
Squamous cell Cav1 negative
Cav1 positive
4
2
5
3     1
Neuroendocrine Cav1 negative
Cav1 positive
7
0
0
0
not 
available
Large cell Cav1 negativeCav1 positive
4
0
2
4    0.1472
Figure 3: Survival curves demonstrating the association between Cav1 expression in brain metastasis and poor 
prognosis (Log rank test, p=0.015).
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among which six displayed a gain and three exhibited 
amplification of Cav1 expression at both the primary and 
metastatic sites. The presence of a gain or amplification 
of expression in the primary neoplasm was significantly 
associated with the same event in the metastasis (Fisher’s 
exact test p = 0.01). None of the cases acquired a gain 
or amplification in the metastatic lesion. The two mutated 
cases showed neither a gain nor amplification. 
Survival analysis of Cav1 expression and 
responsiveness to radiotherapy
Follow-up data, ranging from 1 to 84 months 
(median overall survival: 14 months), were available for 
all but one patient. At the time of analysis, 57 patients 
(84%) had died, all because of brain metastasis. Among the 
11 (16%) who were living, two were Cav1 positive in both 
the primary lung lesion and brain metastasis, whereas one 
had acquired Cav1 expression in the metastasis. Overall, 
although grouping by histotype did not reveal differences 
in survival (log rank test, p = 0.233, Figure 2A), the 
adenocarcinoma histotype was associated with prolonged 
survival (log rank test, p = 0.056, median survival of 19 
vs. 9 months for cases with adenocarcinoma and with 
other histotypes considered together, respectively, Figure 
2B). Only Cav1 expression in the brain metastasis (and 
not its expression in the primary lesion) was related to 
poor prognosis (log rank test, p = 0.015, median survival 
of 18 vs. 10 months for Cav1 negative and positive 
cases, respectively) (Figure 3). The presence of multiple 
metastases vs. a single brain metastasis (20 and 49 
cases, respectively) was not associated with a significant 
difference in survival (log rank test, p = 0.999). With a 
proportional hazard model controlling for age at diagnosis 
(HR = 1.061, 95% CI 1.022 to 1.101, Wald test p = 0.002) 
and the adenocarcinoma histotype (HR = 0.521, 95% CI 
0.301 to 0.901, Wald test p = 0.020), Cav1 expression in 
the metastasis (HR = 2.359, 95% CI 1.309 to 4.251, Wald 
test p = 0.004) was associated with an increased risk of 
death, demonstrating its value as an independent predictor 
(Table 5a). To study the interaction between age and Cav1 
expression at the metastatic site, we considered age as a 
factor, establishing “young” (age below the median of 63) 
and “old” (age ≥ 64) classifications. Interestingly, Cav1-
positive metastasis was associated with an equivalent 
increase in the risk of death in the two age groups 
(interaction term, Wald test p = 0.780) and neutralized 
the favorable effect of young age on survival compared 
with the older patients (old Cav1 negative vs. young Cav1 
positive, HR = 1.058, 95% CI 0.537 to 2.083, Wald test p 
= 0.870) (Table 5b).
Evaluation of the patients with available brain 
radiotherapy data (49 patients, 44 deaths), controlling 
for age at diagnosis, the adenocarcinoma histotype and 
Cav1 expression in the brain metastasis, revealed that 
radiotherapy was not significantly associated with survival 
(Table 6a). However, when accounting for an interaction 
between Cav1 expression and radiotherapy, the treatment 
was associated with a reduced risk of death in the patients 
with Cav1-negative brain metastasis (17 out of 27 cases, 
HR = 0.411, 95% CI 0.175 to 0.966, Wald test p = 0.041) 
and with an increased risk of death in those with Cav1-
positive brain metastasis (14 out of 22 cases, HR = 6.839, 
95% CI 1.849 to 25.301, Wald test p = 0.004) (Table 6b). 
In this subgroup of radiotherapy-treated patients, whole-
brain radiotherapy was administered with adjuvant intent 
to 22 patients with a single surgically removed lesion 
and with palliative-cytoreductive intent to the remaining 
9 patients with multiple brain lesions. Table 7 reports 
an extension of analysis using the proportional hazard 
model, accounting for radiotherapy intent (adjuvant or 
cytoreductive). The hazard ratios were found to be similar 
for the adjuvant and cytoreductive intents (HR = 0.383 
Table 5: Proportional hazard model for the whole data set
Without interaction (a) With interaction (b)
HR p-value HR
--
p-value
Age 1.061 0.002 --
Old age -- -- 2.430 0.026
Histotype 0.521 0.020 0.522 0.021
Cav1 positive metastasis 2.359 0.004 2.571 0.031
Interaction effect Cav1/age -- -- 1.183 0.780
Table 6: Proportional hazard models restricted to radio-treated patients
Without interaction (a) With interaction (b)
HR p-value HR p-value
Age 1.059 0.018 1.069 0.008
Histotype adenocarcinoma 0.388 0.004 0.321 <0.001
Cav1-positive metastasis 3.197 0.003 1.197 0.720
Radiotherapy 1.034 0.920 0.411 0.041
Interaction effect Cav1/Radiotherapy -- -- 6.839 0.004
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vs. HR = 0.475, respectively) and likewise for the two 
interaction terms (Cav1/adjuvant HR = 7.17 vs. Cav1/
cytoreductive HR = 6.534). Model selection based on log-
likelihood ratio tests (p-value = 0.934) favored the model 
with interactions that did not account for the radiotherapy 
intent (Table 6b).
DISCUSSION
In this study, we found that Cav1 expression in 
resected brain metastasis from NSCLC is a reliable 
predictor of poor survival and an independent predictor of 
poor radiotherapy responsiveness.
Prognostic role of adenocarcinoma histotype in brain 
metastasis: Lung cancer is the most frequent site of origin 
for brain metastasis, which is diagnosed in approximately 
20-30% of patients during the course of their disease 
[2]. Approximately half of patients have a single brain 
metastasis [20]. Brain metastasis is more frequently found 
in NSCLC patients [21, 22], and these patients are usually 
considered terminal and to have poor prognosis. According 
to current guidelines [23, 24], resection of solitary brain 
metastasis is a valuable treatment option, resulting in a 
five-year survival rate of 20-25% if radical surgery of 
the primary tumor is also performed [25]. In agreement 
with a recent systematic review [26], survival improves 
when both the primary lung tumor and brain metastasis 
are resected; thus, removal of the primary site and single 
brain metastasis appears to be an effective treatment for 
long-term survival. However, effective tools for selecting 
patients who may benefit from surgical resection of 
brain metastasis remain to be identified. With respect to 
systemic therapy, tumor features, such as the histological 
subtype and molecular signature, play relevant prognostic 
and predictive roles because different NSCLC histologies 
have different treatment approaches and prognoses [27]. 
Surgical resection of brain metastasis from lung squamous 
cell carcinoma results in a significantly worse survival rate 
compared with other histotypes, whereas patients with 
adenocarcinoma live significantly longer [28]. Consistent 
with these findings, we found that the adenocarcinoma 
histotype is associated with prolonged survival, and 
advanced age is linked with poor prognosis.
Prognostic role of Cav1 expression in brain 
metastasis: Expression of Cav1 in human cancer cell lines 
and tumor samples has been documented in numerous 
studies, and it is increasingly clear that its role depends on 
the tumor type and stage [29]. In advanced stages, Cav1 
gains an oncogenic role because its increased level favors 
the development of cellular traits associated with enhanced 
malignancy, including multidrug resistance and metastasis 
[30]. Accordingly, high Cav1 expression is a negative 
prognostic factor for overall and disease-free survival in 
patients with various tumor types, including breast [31], 
esophagus [32], pancreas [33], kidney [34], and prostate 
tumors [35], meningioma [36] and oligodendroglioma 
[37]. Concerning lung cancer, normal human lung 
epithelial cultures abundantly express Cav1, whereas its 
expression is reduced or absent in 95% of small-cell lung 
cancer cell lines and is retained in 76% of NSCLC cells 
[15]. In NSCLC cell lines, Cav1 expression increases 
anoikis resistance, migration and invasiveness [15, 38-
40]. Anoikis-resistant NSCLC cells overexpressing Cav1 
exhibit significant increases in anchorage-independent 
growth, extracellular matrix adhesion, migration, 
and invasion, whereas Cav1 knockdown by shRNA 
transfection is able to reverse the metastatic potential 
[16]. The findings of the present study are consistent 
with those of our previous study of differential Cav1 
expression according to histotype [18], showing that all 
lung large cell neuroendocrine carcinomas and matched 
brain metastases were Cav1 negative. In addition, 20% 
of the primary tumors shifted to Cav1 positivity during 
metastasis. Many studies, including a recent meta-
analysis [17], have confirmed that Cav1 tissue expression 
is a negative prognostic marker in NSCLC and that it is 
correlated with differentiation, T stage and lymph node 
metastasis. However, the clinical significance of Cav1 
expression in resected brain metastasis has not yet been 
investigated. In our study, only Cav1 expression in brain 
metastasis, and not in the primary tumor, was correlated 
with poor prognosis and an increased risk of death in 
the multivariate model, demonstrating its value as an 
independent prognosticator. Moreover, as age is per se an 
adverse prognostic factor, we investigated the relationship 
between age and Cav1 expression at the metastatic 
site, demonstrating that positive Cav1 metastasis was 
independently associated with a higher risk of death, 
exclusively in the group of young patients. 
A somatic missense mutation in CAV1 at codon 
Table 7: Proportional hazard model differentiating for adjuvant or palliative-cytoreductive radiotherapy treatment
HR p-value
Age 1.067 0.014
Histotype adenocarcinoma 0.312 <0.001
Cav1-positive metastasis 1.180 0.740
Adjuvant Radiotherapy 0.383 0.050
Palliative-cytoreductive  Radiotherapy 0.475 0.210
Interaction effect Cav1/ Adjuvant Radiotherapy 7.177 0.007
Interaction effect Cav1/ Cytoreductive Radiotherapy 6.534 0.043
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132, converting proline to leucine (P132L), has been 
detected in 11-16% of invasive breast cancer patients 
[41, 42]. As the recombinant expression of the CAV1 
P132L mutant leads to mislocalization and intracellular 
retention of wild-type CAV1, cellular transformation, and 
promotion of invasive ability [41], a dominant-negative 
behavior has been suggested for the P132L mutant [41, 
43]. Although this mutation was not identified in any of 
46 lung cancer cell lines examined by Sunaga et al. [15] 
and has not been described in other studies investigating 
mutations in lung cancer [38, 44], we detected it in two 
human adenocarcinoma specimens. Both patients with this 
CAV1 P132L mutation had a single brain metastasis, no 
extracranial tumors and a Karnofsky Performance Status 
(KPS) of 90. Their survival times (47 and 49 months) 
were longer than the median survival time of the series (14 
months). These findings indicate that mutation of CAV1 
results in a loss of its unfavorable prognostic/predictive 
value, in contrast with what has been previously described 
in different oncologic contexts [43].
Predictive role of Cav1 for radiotherapy 
responsiveness in brain metastasis: In solitary brain 
metastasis, surgical resection followed by WBRT or 
stereotactic radiosurgery might be beneficial [2]. However, 
the adjuvant treatment of these patients still results in 
disappointing outcomes because WBRT only extends 
survival by three to six months, even when achieving 
palliative improvement of neurological symptoms [3]. In 
our series, radiotherapy was not significantly associated 
with survival. Nevertheless, among the radiotherapy-
treated patients, independent of the intent, Cav1 proved 
to be a useful marker for predicting radiotherapy 
responsiveness because the patients with Cav1-negative 
brain metastasis had a reduced risk of death, whereas 
those with Cav1 positivity showed an increased risk. 
These findings are consistent with reports of induction of 
radiosensitization by Cav-1 knockdown in the same tumor 
model [10, 11] and radiation-elicited Cav1 expression in 
pancreatic cancer cell lines [10]. Moreover, low Cav1 
expression in pre-treatment biopsies from patients with 
locally advanced colorectal cancer has been correlated 
with better rates of local control and overall survival [12].
CONCLUSIONS
Cav1 expression in brain metastasis from lung 
cancer is independently predictive of worse outcome and 
radioresistance. Therefore, in the future development of 
personalized therapy for advanced oncologic patients, 
Cav1 could become an additional tool to prognosticate 
and predict a distinguished subset of patients with brain 
metastatic lung cancer. 
MATERIALS AND METHODS
Case collection
Sixty-nine NSCLCs and their matched resected 
brain metastases were retrieved from consecutive cohorts 
from the archives of two different institutions, the 
Pathology Divisions of the University of Torino at Città 
della Salute e della Scienza (Molinette) Hospital in Turin 
and San Luigi Hospital in Orbassano, Italy. In 25 cases 
(36%), brain metastasis was diagnosed synchronously with 
primary NSCLC, and in three cases (4%), brain metastasis 
was diagnosed prior to primary lung cancer (1 to 3 months 
before). In the remaining 41 cases (64%), metastasis was 
metachronous (mean of 9 months from NSCLC diagnosis, 
range 1-63). None of the patients had extra-cranial tumors. 
At the time of neurosurgical resection, the patients with a 
single brain metastasis comprised 71% of the total patients 
(49 patients), whereas the remaining 29% of the patients 
(20 patients) had multiple metastases. The patients with a 
single brain metastasis underwent conventional surgery. 
Thirteen out of 69 patients received chemotherapy. 
Information about brain radiotherapy was available for 49 
patients. Among them, 22 patients with a single surgically 
removed lesion received radiotherapy with an adjuvant 
intent; conversely, nine patients with multiple brain lesions 
underwent radiotherapy with a palliative-cytoreductive 
intent. Whole-brain radiotherapy was administered with 
the same schedule (30 Gy in 10 fractions) in both patient 
groups. The group of patients treated with adjuvant 
radiotherapy had a good clinical performance status (mean 
KPS of 90) without any significant neurological deficits. 
The patients treated with cytoreductive whole-brain 
radiotherapy for active metastatic disease occasionally 
had some neurological deficits related to the site of the 
disease, but the KPS did not fall lower than 70, which 
is mandatory for irradiation. Similarly, all of the patients 
who did not receive radiotherapy had a KPS of over 70. 
All of the case data were anonymously recorded. The 
study received ethical approval from the local Institutional 
Review Boards.
Histopathological evaluation
All hematoxylin and eosin (H&E)-stained slides 
available from surgical specimens were reviewed, and 
a representative paraffin block was selected for each 
case. The primary tumor and matched brain metastasis 
from each patient were independently reviewed by two 
dedicated pathologists (RS and PC), who confirmed 
all diagnoses according to the current World Health 
Organization classification [19].
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Immunohistochemistry
Immunohistochemistry was performed in all cases. 
Three micrometer-thick serial paraffin sections for each 
case were processed by immunohistochemistry using 
an antibody against Cav1 (Santa Cruz, Santa Cruz, CA, 
USA, rabbit polyclonal, diluted 1/350) with an automated 
immunostainer (Ventana BenchMark Auto-Stainer, 
Ventana Medical Systems). A biotin-free, dextran chain-
based detection system (EnVysion, Dako, Carpinteria, CA, 
USA) was used for visualization, and diaminobenzidine 
(Ventana Medical Systems, Tucson, AZ, USA) was used 
as a chromogen, according to standard protocols. Vascular 
endothelium represented an internal positive control.
Staining interpretation and scoring system
All immunostained slides were analyzed 
independently by RS, ED and PC, who were blinded to the 
clinical data. Cav1 staining was assessed as a categorical 
variable (negative or positive if present in at least 10% 
of neoplastic cells). In cases of discrepancies, slides were 
reviewed using a multihead microscope, and a consensus 
was reached.
Mutational analysis
Mutational analysis of the Cav1 gene was performed 
in 54 cases (in both the primary tumor and metastasis) to 
identify somatic mutations. Genomic DNA extractions 
were performed with standard methods (NucleoSpin Tissue 
Kit, Macherey-Nagel, Duren, Germany), and 6 ng of DNA 
was amplified using specific primers for the human Cav1 
gene. Specifically, PCR primers were designed to amplify 
and sequence exon 2 and exon 3 of Cav1 as follows: Cav-
1F-exon2: 5’-GCAGGGACATCTCTACACG-3′; Cav-1R-
exon2: 5’-GCCTTGGCTTACCTTGACCA-3′; Cav1F-
exon3: 5’-AACCAGAAGGGACACACAG-3′; and 
Cav-1R-exon3: 5’-AAAGAGTGGGTCACAGACG-3′.
The somatic origin of each mutation was confirmed 
by the sequencing of both neoplastic and normal DNA 
obtained by laser-capture microdissection of a non-
transformed area adjacent to the neoplastic lesion. 
For small samples, normal DNA was extracted from a 
different histological specimen collected from the same 
patient. Mutations were detected only in malignant tissues. 
Positive results for mutational analysis were validated at 
least twice in independent PCRs. Pathologists carrying out 
these analyses were blinded to the clinical outcomes of the 
patients.
Cav-1 fluorescence in situ hybridization (FISH) 
analysis
 FISH was performed using both an alpha satellite 
probe specific for chromosome 7 (CEP7) directly labeled 
with green fluorochrome (Cytocell Technologies Ltd., 
UK) as a control probe and a self-made probe specific 
for the CAV1,2 locus, BAC 688K20 (7q31.2). The clone 
was obtained from Invitrogen (Invitrogen Corporation, 
USA). UCSC database (http://genome.ucsc.edu July 2008 
release) was queried for the localization of the probe. The 
BAC was expanded, extracted and then directly labeled 
with SpectrumOrange-dUTP (Abbott Molecular, Europe) 
using a BioPrime DNA Labeling System (Invitrogen 
Corporation, USA), according to the manufacturer’s 
instructions. To analyze the position and strength of the 
signal, the presence/absence of background and cross-
hybridization, and the hybridization efficiency, the 
BAC clone was tested using metaphase and interphase 
cells from healthy donors obtained using conventional 
cytogenetic methods. FISH was routinely performed 
with the two probes CAV1,2 and CEP7 on formalin-
fixed, paraffin-embedded tissue. Images of red (CAV1,2) 
and green (CEP7) spots in areas with significant signal 
were automatically acquired using 13 focus planes, with 
Metafer software by a MetaSystem scanning station 
(Carl Zeiss MetaSystems GmbH, Altlussheim, Germany) 
equipped with an AxioImager epifluorescence microscope. 
The automatically acquired images were analyzed with Isis 
software (Zeiss). Eighty to 100 non-overlapping neoplastic 
nuclei with two control green signals (2G) were analyzed 
for each case and were scored as follows: 2R, normal 
nuclei; R  > 3, CAV gain; R >  5, CAV amplification; and 
R < 2, CAV loss.
Statistical analysis
Correlations between Cav1 expression and the 
clinico-pathological variables were quantified using 
the chi-square test or Fisher’s exact test, as appropriate. 
Kaplan-Meier curves and the log rank test were used 
to assess differences in survival between the groups of 
patients. Overall survival was defined as the time elapsed 
from the date of lung cancer diagnosis to the date of death 
or the last visit. Hazard ratios (HRs) and 95% confidence 
intervals (CIs) were estimated by the Cox proportional 
hazards model for multivariate survival analysis. The log-
likelihood ratio test based on a chi-square approximation 
was used to perform model selection as appropriate. 
Statistical significance was set at a level of 0.05. All 
analyses were conducted using version 2.12.1 of R 
statistical package (www.r-project.org).
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